The malaria community has done a great job over the past decade to combat the disease. But this may be about to change.

There are always costs of both action and inaction; however, before a costly scheme is funded, better evidence of its effectiveness should be established.

The Global Fund is to be commended for its transparency, but it has failed to act on the information it has gleaned, and continues to allow its funds to be used by governmental distribution systems known to be corrupt.

The high persistence of substandard drugs and clinically inappropriate artemisinin monotherapies inAfrica risks patient safety and endangers the future of malaria treatment.

Debates about which tools and strategies work best against malaria are fraught, but there are some things that can be agreed upon.

Today, nearly 80 percent of active pharmaceutical ingredients originate outside the United States. But the FDA cannot adequately oversee the safety of chemicals manufactured overseas and imported into the United States.

Problems with procurement, corruption, and intellectual property threaten new and innovative malaria treatments.

The Food and Drug Administration must use rigorous drug trials, but these tests should not be so strict as to deny cancer patients access to potentially lifesaving drugs.